Screening method and application of early prediction marker of papillary thyroid cancer
By detecting the expression level of P4HA2 and using P4HA2 inhibitors, the accuracy and specificity problems of early diagnosis of thyroid cancer are solved, efficient and simple early screening is achieved, invasive testing is reduced, and personalized treatment is promoted.
Patent Information
- Application Number
- CN202510897588.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-14
- Publication Date
- 2025-10-14
AI Technical Summary
Existing early diagnosis technologies for thyroid cancer have limitations in accuracy, specificity, and operational complexity, making it difficult to effectively distinguish between benign and malignant nodules. Existing biomarkers lack specificity and sensitivity, leading to a high risk of misdiagnosis and missed diagnosis, and invasive testing increases the burden on patients.
By detecting the expression level of P4HA2, using P4HA2 mRNA and protein levels as biomarkers, combining weighted gene co-expression network analysis and machine learning algorithms, P4HA2 is screened out as an early predictive marker for papillary thyroid cancer, and P4HA2 inhibitors such as siRNA are used to inhibit cell proliferation and migration, and kits, chips or high-throughput sequencing platforms are developed for detection.
It improves the accuracy and specificity of early diagnosis of thyroid cancer, reduces unnecessary invasive testing, provides new perspectives for molecular mechanism research, promotes personalized treatment strategies, and reduces the psychological and physical burden on patients.
Smart Images

Figure CN120775978A_ABST
Abstract
Description
[0001] The present application is a divisional application of a Chinese invention patent with the application date of "2025.03.14", the application number of "202510303306.2", and the invention name of "Papillary thyroid cancer early prediction marker, use and screening method thereof". TECHNICAL FIELD
[0002] The present application relates to the field of biological analysis technology and medical technology, in particular to a screening method for a papillary thyroid cancer early prediction marker and application thereof. BACKGROUND
[0003] Thyroid cancer is currently ranked seventh in the global total incidence rate, and it is mainly divided into three histological types: (1) differentiated thyroid cancer, including papillary carcinoma, follicular carcinoma and oxyphilic carcinoma; (2) medullary thyroid carcinoma; (3) undifferentiated thyroid carcinoma. Differentiated thyroid cancer is the most common pathological type, accounting for about 90% of malignant thyroid tumors, and the incidence rate in females is significantly higher than that in males.
[0004] In the early diagnosis of thyroid cancer, the existing technical methods still have some important limitations and deficiencies. First, fine needle aspiration biopsy (FNA) as one of the most commonly used methods for diagnosing thyroid cancer has certain limitations. Although FNA has certain diagnostic value, its accuracy is affected by factors such as sample quality, operator experience and lesion site, especially in cytological evaluation, sometimes there are ambiguous or suspicious results. In addition, the invasive nature of FNA can cause certain pain and psychological stress to patients, and may cause complications in some patients. Second, the specificity and sensitivity of existing thyroid cancer prediction biomarkers are still insufficient. Currently used molecular markers for diagnosing thyroid cancer, such as thyroid globulin (Tg) or carcinoembryonic antigen (CEA), have insufficient specificity in some cases, which makes it difficult to distinguish between benign and malignant lesions, increasing the risk of misdiagnosis and missed diagnosis. In addition, the lack of specific and highly sensitive biomarkers makes it difficult to detect thyroid cancer at an early stage, which may cause patients to miss the best treatment window.
[0005] In addition, the current diagnosis of thyroid cancer still relies on imaging methods such as ultrasound imaging, although these methods can detect thyroid nodules, they have limitations in distinguishing between benign and malignant nodules. The results of ultrasound imaging are greatly influenced by the subjective judgment of the operator, and some benign nodules and malignant nodules have similar characteristics in imaging, which makes it difficult to accurately distinguish between them. Further examination often needs to combine other detection methods, which increases the complexity of the diagnosis process and the burden on patients.
[0006] In addition, existing diagnostic methods lack a high-efficiency, simple, and widely applicable detection method. Most existing detection methods require complex laboratory operations and expensive equipment, which limits their application in primary medical units. Patients need to go through multiple complex steps to be diagnosed, which not only increases the time cost of diagnosis, but also may delay treatment.
[0007] In summary, existing early diagnosis techniques for thyroid cancer have many limitations in accuracy, specificity, patient experience, and operational complexity. Therefore, there is an urgent need to develop a new, biomarker-based detection method that can improve the accuracy and specificity of early diagnosis of thyroid cancer, while simplifying the detection process, reducing the invasiveness to patients, and improving the feasibility of clinical application.
[0008] Although the overall prognosis of thyroid cancer is good, the risk of tumor metastasis and recurrence is very high. About 30% of differentiated thyroid cancer (DTC) patients experience recurrence and distant metastasis. Therefore, cancer cells may exhibit reduced uptake of radioactive iodine, gradually lose sensitivity to radioactive iodine (RAI) therapy, and eventually transform into radioactive iodine-refractory differentiated thyroid cancer. The overall 10-year survival rate of radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) is 10%, and the median survival is only 3-5 years. In addition, anaplastic thyroid cancer (ATC) has a median overall survival (OS) of 4 months since diagnosis, and the disease-specific mortality rate is close to 100%. Thyroid cancer not only has a significant impact on individuals' physical and mental health, but also causes significant economic and social burden to the whole society. Therefore, finding new high-specificity and high-sensitivity predictive markers is crucial for the early diagnosis of thyroid cancer. New biomarkers not only can improve the accuracy of diagnosis, but also can reduce the risk of misdiagnosis and missed diagnosis, especially in the early stage. Early detection of thyroid cancer is crucial for improving the survival rate and quality of life of patients, and the limitations of existing technologies have caused many patients to miss the best treatment opportunity. By developing new predictive markers, early screening can be better achieved, helping to distinguish between benign and malignant nodules, reducing unnecessary invasive detection, and reducing the psychological and physical burden on patients. At the same time, new markers can also promote more precise personalized treatment strategies, thereby providing better medical services for patients.
[0009] The foregoing background knowledge is intended to help those of ordinary skill in the art understand the prior art closest to the present application, and facilitate the understanding of the inventive concept and technical solutions of the present application. It should be clear that, in the absence of explicit evidence that the above background technology was disclosed before the filing date of the present patent application, the above background technology should not be used to evaluate the inventiveness of the technical solutions of the present application. SUMMARY
[0010] Technical problems In order to solve the above problems, the purpose of the present application is to provide a screening method and application of a papillary thyroid cancer early prediction marker, which can be used for the prediction of papillary thyroid cancer and its early prediction, and the knockdown of the marker can also be used for the prediction of papillary thyroid cancer and its early prediction, so that early screening can be better completed, benign and malignant nodules can be distinguished, unnecessary invasive detection can be reduced, and a new perspective is provided for the molecular mechanism research and early diagnosis of thyroid cancer.
[0011] Technical solutions That is, the present application includes the following solutions.
[0012] Solution 1, use of a reagent for detecting the expression level of P4HA2 in the preparation of a product for predicting papillary thyroid cancer.
[0013] Further, the expression level of P4HA2 includes at least one of the P4HA2 mRNA level and the P4HA2 protein level.
[0014] Further, the product is used for predicting early papillary thyroid cancer.
[0015] Further, the product includes at least one of a kit, a chip, a test paper, or a high-throughput sequencing platform.
[0016] Solution 2, a P4HA2 inhibitor, including a substance for knocking down the expression of a P4HA2 gene, which is an siRNA specifically interfering with the expression of a P4HA2 gene; the substance for knocking down the expression of a P4HA2 gene is selected from at least one of the following siRNA molecular sequences: SEQ IN NO1: GAAGGTGACTACCGAACAA, SEQ IN NO2: GCCGAATTCTTCACCTCTA, and SEQ IN NO3: GCTGCAATTTGGCCTAAGA.
[0017] Further, the siRNA molecule is loaded on a pharmaceutically acceptable transfection carrier.
[0018] Solution 3, use of a P4HA2 inhibitor in the preparation of a product for inhibiting the migration and / or proliferation of thyroid cancer cells, wherein the P4HA2 inhibitor is a specific small interfering siRNA targeting P4HA2.
[0019] Further, the product is a drug.
[0020] Further, the thyroid cancer is papillary thyroid cancer.
[0021] Scheme 4, an application of siRNA for knocking down P4HA2 in the preparation of an inhibitor of papillary thyroid carcinoma activity.
[0022] Further, the molecular sequence of the siRNA is selected from at least one of the following sequences: SEQ IN NO1: GAAGGTGACTACCGAACAA, SEQ IN NO2: GCCGAATTCTTCACCTCTA, and SEQ IN NO3: GCTGCAATTTGGCCTAAGA.
[0023] Scheme 5, a screening method for biomarkers of papillary thyroid carcinoma, comprising: 1) Based on weighted gene co-expression network analysis, calculate the Pearson correlation coefficient between genes, determine gene modules, construct a co-expression network, identify the association between modules and features, and screen out potential hub genes. 2) Based on support vector machine recursive feature elimination, LASSO regression and random forest method, a screening model is constructed, and the intersection of the screening results is obtained, and the intersection of the potential hub genes is obtained, and an intersection list containing six candidate genes is obtained, including P4HA2, TBC1D4, PLSCR4, PRKCQ, AIF1L and ANGPTL1. 3) Overexpression verification shows that P4HA2 promotes cancer cell proliferation, and knockdown verification shows that P4HA2 inhibits cancer cell proliferation, and P4HA2 is screened as a biomarker for predicting papillary thyroid carcinoma or predicting early papillary thyroid carcinoma.
[0024] In step 1), the Pearson correlation coefficient between genes is calculated, the gene modules are determined, the co-expression network is constructed, and the association between modules and features is identified, and the potential hub genes are screened out, which specifically includes: calculating the Pearson correlation coefficient between genes, and selecting an appropriate soft threshold to make the network comply with the scale-free network distribution; according to the soft threshold, the correlation matrix is converted into an adjacency matrix, and then a topological overlap matrix is generated; based on the topological overlap matrix, hierarchical clustering is performed on the genes, a hierarchical clustering tree is constructed, and different branches represent different modules; each module contains at least 30 genes, and then similar modules are merged according to a height threshold of 0.25; the core genes of the core module are intersected with the DEGs, and finally the potential hub genes are screened out.
[0025] In step 3), siRNA is used for knockdown verification, and the molecular sequence of the siRNA is selected from at least one of the following sequences: SEQ IN NO1: GAAGGTGACTACCGAACAA, SEQ IN NO2: GCCGAATTCTTCACCTCTA, and SEQ IN NO3: GCTGCAATTTGGCCTAAGA.
[0026] Scheme 6, a computer device, the computer device includes a memory, a processor, a communication interface and a communication bus;Wherein, the memory, the processor, the communication interface through the communication bus each other communication;The memory is used to deposit computer program;The processor is used to execute the computer program deposited on the memory, the processor executes the computer program when realizes at least one step of the foregoing prediction papillary thyroid carcinoma biomarker screening method.
[0027] Scheme 7, a computer readable storage medium, the computer readable storage medium has computer program, the computer program is executed by processor to realize at least one step of the foregoing prediction papillary thyroid carcinoma biomarker screening method.
[0028] On the basis of conforming to the common sense of the art, the above-mentioned preferred conditions can be combined with each other to obtain the specific embodiments.
[0029] Beneficial effects According to the present application, the inventors screened potential hub genes through weighted gene co-expression network analysis, and then screened gene features using multiple advanced machine learning algorithms, so as to identify key genes closely related to the occurrence and development of thyroid cancer from complex gene expression data, and then found that the expression level of P4HA2 in thyroid cancer tissue was significantly higher than that in normal thyroid tissue, and knocking down P4HA2 inhibited the proliferation of tumor cells, so P4HA2 can be used as a marker for early prediction of papillary thyroid carcinoma, which provides a new perspective for the molecular mechanism research and early diagnosis of thyroid cancer.
[0030] The present application adopts the above technical solutions to achieve the above-mentioned purposes, and makes up for the shortcomings of the prior art. BRIEF DESCRIPTION OF DRAWINGS
[0031] In order to make the above and / or other purposes, features, advantages and examples of the present application more obvious and easy to understand, the drawings needed in the specific embodiments of the present application will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application, and other drawings can be obtained by those skilled in the art without creative labor.
[0032] Figure 1 The volcano plot of differential genes is shown; Figure 2 The LASSO logistic regression coefficient cross-validation error chart is shown; Figure 3 The LASSO regression coefficient penalty chart is shown; Figure 4 The random forest error curve chart is shown; Figure 5 shows a random forest feature importance plot; Figure 6 shows a SVM cross-validation root mean square error plot; Figure 7 shows a P4HA2 mRNA expression schematic; Figure 8 shows a P4HA2 protein expression schematic; Figure 9 shows a box plot of intersecting gene expression; Figure 10 shows a box plot of immune infiltrates; Figure 11 shows a Western Blot plot of P4HA2 knockdown; Figure 12 shows a Western Blot plot of P4HA2 overexpression; Figure 13 shows a CCK-8 proliferation plot; Figure 14 shows a colony formation plot; Figure 15 shows a cell scratch plot; Figure 16 shows a Transwell migration plot. DETAILED DESCRIPTION
[0033] Those skilled in the art can readily implement the present application using the methods and materials described herein, while still others can apply the present application in contexts not specifically described herein. However, even though particular embodiments of the application have been described herein, it is anticipated that applicants will devise numerous other embodiments that fall within the scope of the present application. Accordingly, there is no intention that the application be limited as described herein, but rather the application is to be as broad as the claims herein will allow.
[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The methods and materials described herein will be practiced by, but not limited to, those skilled in the art. Other suitable methods and materials known to those of ordinary skill in the art can also be used. The materials, methods, and examples described herein are illustrative only and are not intended to be limiting. All publications, patent applications, patents, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
[0035] The materials, methods, and examples described herein are illustrative only and not limiting. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, suitable methods and materials are described herein.
[0036] The technical solutions in the embodiments of the present application will be clearly and completely described below. Obviously, the described embodiments are only a part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by a person of ordinary skill in the art without creative effort belong to the protection scope of the present application. Meanwhile, the embodiments in the present application and the features in the embodiments can be combined with each other without conflict.
[0037] It should be understood that any technical solution claimed by the present application does not involve the diagnosis and treatment of diseases.
[0038] In addition, the test methods used in the embodiments are conventional methods unless otherwise specified; the materials, reagents, etc. used are commercially available unless otherwise specified. The reagents or instruments not marked with manufacturers are conventional products that can be obtained by market purchase. All the publications and other references mentioned in the present application are incorporated by reference in their entirety.
[0039] The present application is described in detail below Embodiment 1 Taking the transcriptome gene expression data of 507 thyroid cancer (THCA) patients and the corresponding clinical information as a data source as an example, a screening method of biomarkers for predicting papillary thyroid cancer is provided, which specifically includes the following steps.
[0040] Screening and analysis of differentially expressed genes (DEGs): using the "limma" package (version: 4.1.2) in R software, the differentially expressed genes (DEGs) between THCA and normal samples are screened by the threshold of FDR<0.05 and |log2 fold change (FC)|>1. The volcano plot and heat map of the differential genes are visualized by the "ggplot2" (version: 3.4.2) package. In the volcano plot, the DEGs with log2FC<-1 are defined as down-regulated genes, and the DEGs with log2FC>1 are defined as up-regulated genes. The DEGs results are shown in Figure 1 Figure 1 By comparing the gene expression data of normal samples and disease samples, a total of 2728 differentially expressed genes are screened out, and each point in the figure represents a gene, which intuitively identifies the genes that are significantly up-regulated or down-regulated in the disease state.
[0041] We used the R software "WGCNA" package to construct the WGCNA network to identify the module with the highest correlation with THCA. The Pearson correlation coefficient between genes was calculated, the gene module was determined, the co-expression network was constructed, the association between the module and the characteristics was identified, and the potential hub genes were screened out. Specifically, the Pearson correlation coefficient between genes was calculated, and an appropriate soft threshold was selected to make the network consistent with the scale-free network distribution. According to the soft threshold, the correlation matrix was converted into an adjacency matrix, and then a topological overlap matrix (TOM) was generated. Based on the TOM, the genes were hierarchically clustered, a hierarchical clustering tree was constructed, and different branches represented different modules. Each module contained at least 30 genes, and then similar modules were merged according to a height threshold of 0.25. After taking the intersection of the core genes of the key module screened out by the WGCNA network and the DEG result, 206 potential hub genes were finally screened out.
[0042] To further explore the potential biological functions of these key genes, we constructed KEGG analysis and GO analysis. KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis is a database used to understand high-level biological functions and systemic functions. KEGG helps researchers better understand the relationship between genes and metabolic processes by linking genes to metabolic pathways. In thyroid cancer research, KEGG pathway analysis can reveal cancer-related signaling pathways, helping to understand the molecular mechanisms of cancer and providing references for discovering new therapeutic targets. GO (Gene Ontology) is a standardized gene function classification system mainly used to describe the functional attributes of genes and gene products. GO annotation includes three major categories: Biological Process, Molecular Function, and Cellular Component. In thyroid cancer research, GO analysis can help identify genes related to specific biological processes or functions, revealing the roles of these genes in cancer initiation and progression. By combining KEGG and GO annotation, researchers can better understand the functional characteristics and metabolic pathways of thyroid cancer-related genes, providing important reference information for biomarker screening and functional verification. The results of Go enrichment analysis can be used to identify the biological functions and molecular pathways involved in differentially expressed genes. In terms of biological processes, they are mainly enriched in the regulation of apoptosis signaling, neural system development, and thyroid hormone metabolism; in terms of cellular components, these key genes are mainly involved in extracellular matrix, endoplasmic reticulum, and matrix membrane; in terms of molecular function, these key genes are mainly concentrated in sulfur compound binding and organic anion transmembrane transporter activity. KEGG pathway enrichment analysis can be used to identify the metabolic pathways and signaling pathways enriched by differentially expressed genes, indicating that these key genes are mainly enriched in 15 pathways, such as apoptosis and autophagy, thyroid hormone signaling pathway, TGF-β signaling pathway, and cell adhesion.
[0043] Based on LASSO regression, random forest, and support vector machine recursive feature elimination (SVM-RFE algorithm), we constructed a screening model to identify key genes closely related to the occurrence and development of thyroid cancer from complex gene expression data. LASSO regression compresses the coefficients of unimportant features by introducing a penalty term, thereby achieving feature selection, Figure 2 The LASSO logistic regression coefficient cross-validation error results are shown, which show the error changes of the LASSO (Least Absolute Shrinkage and Selection Operator) logistic regression model during cross-validation, Figure 3LASSO regression coefficient penalty is shown, which shows the regression coefficient size corresponding to different penalty coefficients in LASSO regression, for selecting the optimal penalty coefficient to balance the bias and variance of the model. Random forest is an ensemble learning method that improves the accuracy and stability of prediction by constructing multiple decision trees and outputting the average result, Figure 4 Random forest error curve is shown, which shows the change of error in the training process of the random forest model, for evaluating the stability and prediction ability of the model; Figure 5 Random forest feature importance score is shown, which is used to identify the genes or features that contribute most to the model prediction. SVM-RFE algorithm identifies key genes by recursively eliminating the least important features, combined with the powerful classification ability of support vector machine, Figure 6 SVM cross-validation root mean square error is shown, which shows the root mean square error (RMSE) of the support vector machine (SVM) model in the cross-validation process, for evaluating the prediction performance of the model. By integrating the intersection of the screening results of the three algorithms and intersecting with the 206 potential hub genes, we obtained an intersection list containing six candidate genes, which showed potential as early prediction markers for thyroid cancer. These genes include P4HA2, TBC1D4, PLSCR4, PRKCQ, AIF1L and ANGPTL1. It is worth noting that the expression level of P4HA2 in thyroid cancer tissue is significantly up-regulated compared with normal thyroid tissue, while the expression levels of the other five genes show a downward trend.
[0044] Among them, the SVM-RFE algorithm identifies key genes by recursively eliminating the least important features, combined with the powerful classification ability of support vector machine, which includes: (1) Obtain feature sample data , which is divided into K subsets: So that: randomly select K samples from n sample data as the initial cluster center, and the remaining sample data is respectively classified into the class with the nearest cluster center, and the total distance in the class is minimized, and the objective function is: , where represents the cluster center point of the set , the t+1th class center point is updated by the following formula: , the new cluster center repeats the above steps for iteration until all data converges to the corresponding cluster set, so that the sum of the squared distances from each data point in each cluster set to the cluster center is minimized or reaches a predetermined value or iterates to the upper limit, and the set of all cluster centers is denoted as ; (2) Use SVM-RFE algorithm to sort each subset completed in step (1) and select A key feature, all key features constitute a new feature set ; (3), using the SVM-RFE algorithm again to sort the new feature set composed of , obtain the final importance analysis result, and obtain the key feature set , the number of features is denoted as , and . The SVM-RFE algorithm can eliminate unimportant secondary features through a recursive method, but the similarity redundancy caused by the linear or nonlinear relationship between features will affect the judgment of key features, so the application combines the clustering algorithm with the SVM-RFE algorithm, and the clustering center and the key features obtained by the SVM-RFE algorithm of each clustering subset are screened again by the SVM-RFE algorithm, so as to obtain the key features, which can significantly reduce the overall operation amount, quickly and accurately determine the key features containing the target gene, better consider the correlation between features, and avoid information loss in the feature selection process; in addition, by limiting , and , when , the classification performance is significantly improved compared to not clustering, which can further improve the classification accuracy, quickly remove redundant features, achieve the purpose of selecting features, and better sensitivity and specificity, which can also effectively prevent message loss, for example, when , the final ANGPTL1 feature will be accidentally lost, so the embodiment further combines LASSO regression and random forest method to screen the accurate candidate gene intersection list after optimizing the SVM-RFE algorithm.
[0045] Example 2 On the basis of the foregoing embodiment, the expression of P4HA2 in the thyroid cancer cell line is verified.
[0046] The mRNA expression level and protein expression level of P4HA2 in a plurality of thyroid cancer cells and a human thyroid normal cell were detected, and the results are shown in Figure 7 and Figure 8 , the results show that the mRNA level and protein expression of P4HA2 in FTC238, FTC133, TPC-1, and K1 cell lines are higher than that in NTHY cell line. We selected FTC238, TPC-1, and K1 for subsequent experiments.
[0047] qPCR is a nucleic acid quantification technique that monitors fluorescence signals in real-time during DNA amplification. In this study, we used qPCR to quantitatively analyze the mRNA expression level of P4HA2 gene. The experimental steps are as follows: collect 10 cell lines, extract total RNA, and convert the extracted total RNA into cDNA using reverse transcriptase. Perform qPCR amplification in a reaction system containing specific primers and SYBR Green I fluorescent dye. By monitoring the increase in fluorescence signals in real-time, the expression level of the target gene is quantified.
[0048] Western Blot technology, as an immunological method for detecting the expression level of specific proteins in cell or tissue extracts, has been widely used in biomedical research. This technology combines specific primary antibodies with antigenic epitopes of target proteins, then uses secondary antibodies labeled with enzymes or fluorophores to bind to primary antibodies, and finally visualizes the presence and abundance of target proteins through a chemiluminescence or fluorescence detection system. In this study, WB experiments were used to analyze the expression of P4HA2 protein in thyroid cancer cell lines. The specific experimental steps are as follows: first, collect the proteins of 10 cell lines and extract the proteins through appropriate lysis buffer. Then, use SDS-PAGE to separate the protein samples by electrophoresis to ensure that the protein samples can be effectively separated in the gel according to their molecular weight. After electrophoresis, the proteins in the gel are transferred to a solid support (such as PVDF) by wet transfer or semi-dry transfer. This step is crucial in the WB experiment, as it determines the efficiency and specificity of subsequent antibody binding. After transferring the membrane, use appropriate blocking solution (such as skimmed milk powder) to block the membrane to reduce non-specific binding. Then, incubate the membrane with specific primary antibodies to recognize and bind to P4HA2 protein. After incubation with primary antibodies, wash thoroughly with TBST buffer to remove unbound primary antibodies. Then, incubate the membrane with secondary antibodies, which can recognize the constant region of primary antibodies and amplify the signal through enzyme-labeled secondary antibodies. Finally, develop the image by ECL chemiluminescence method, and capture and analyze the band signal of P4HA2 protein using a chemiluminescence imaging system.
[0049] Figure 9 The box plot of the intersection gene expression is shown, which shows the expression difference of the six genes in the intersection between tumor samples and normal samples. The box plot directly shows the distribution and difference of gene expression. The mRNA and protein expression of P4HA2 in thyroid cancer cell lines were quantitatively analyzed by qPCR and WB techniques, and the results showed that P4HA2 was significantly up-regulated in thyroid cancer cell lines, while the other five intersection genes were down-regulated in thyroid cancer cell lines.
[0050] Example 3: On the basis of the foregoing examples, immunohistochemical analysis was performed.
[0051] Immune infiltration analysis We used CIBERSORT algorithm to calculate the immune cell infiltration between high-risk score group and low-risk score group. The reference dataset was derived from CIBERSORT (https: / / cibersortx.stanford.edu / inc / inc.download.page.handler.php?file=LM22.txt). This dataset recorded the gene expression characteristic data of 22 immune cells. The relative abundance of 22 immune cell subgroups in each sample was calculated, and each sample was calculated 1000 times. We used single sample Gene Set Enrichment Analysis (ssGSEA) in GSVA R package to analyze the infiltration degree of 28 different immune cell types between high-risk score group and low-risk score group. The "pheatmap" package was used to draw the heat map, and the "reshape2" and "ggpubr" packages were used to draw the box plot. Finally, the pROC R package was used to calculate the area under the receiver operating characteristic curve (AUC value). Figure 10 Immune infiltration box plot, which shows the expression level of different immune cell types in tumor samples, uses box plot to intuitively show the distribution and difference of immune cell expression, according to Figure 10 The results show that: the high expression group of P4HA2 has reduced activated CD4 T cells, monocytes, Th1 and Th2 cell infiltration, increased activated dendritic cells, macrophage infiltration, MDSC, T-regs cell. It shows that the high-risk group may inhibit the activation of anti-tumor immune response, weaken the ability of the body to clear the tumor, tend to immune suppression, help tumor immune escape and disease progression.
[0052] Example 4: On the basis of the foregoing examples, knockdown and overexpression are verified.
[0053] To verify the function of P4HA2 as an early prediction marker of thyroid cancer, we used RNA interference technology (RNAi) to specifically knock down the P4HA2 gene and plasmid-mediated overexpression experiments. The knockdown experiment was achieved by transfecting P4HA2-specific siRNA (small interfering ribonucleic acid), and the experimental group was divided into Si-NC (negative control group), Si-1, Si-2, Si-3, and Si-RNA sequences were as follows: genOFFTM st-h-P4HA2_001: GAAGGTGACTACCGAACAA; genOFFTM st-h-P4HA2_002: GCCGAATTCTTCACCTCTA; genOFFTM st-h-P4HA2_003: GCTGCAATTTGGCCTAAGA.
[0054] In the overexpression experiment, we used different concentration gradients of plasmid Vector (0.25 μg / mL, 0.5 μg / mL, 0.75 μg / mL, 1 μg / mL) as the control group, and OE (0.25 μg / mL, 0.5 μg / mL, 0.75 μg / mL, 1 μg / mL) as the P4HA2 overexpression group. Figure 11 The Western Blot graph for P4HA2 knockdown is, Figure 12 The Western Blot graph for P4HA2 overexpression, the experimental results show that the knockdown effect of Si-2 and Si-3 groups is better, and the overexpression effect of 1 μg / mL is the best.
[0055] Example 5: On the basis of the foregoing examples, CCK-8 proliferation experiments were performed.
[0056] CCK-8 (Cell Counting Kit-8) is a modified method based on MTT, the principle of which is that WST-8 in the reagent is reduced to water-soluble yellow formazan product under the action of cell mitochondrial dehydrogenase, and the color depth is proportional to the number of living cells. In the experiment, we set up Vector, OE (P4HA2 overexpression group) and Si-NC, Si-P4HA2 (P4HA2 knockdown group) control and experimental groups to evaluate the effect of P4HA2 on cell proliferation.
[0057] 1. Cell culture: The thyroid cancer cell lines were inoculated into 96-well plates, 100 μL of culture medium containing 3000 cells was added to each well.
[0058] 2. Time point setting: CCK-8 treatment was performed on the cells in each group at 0h, 24h, 48h, 72h, and 96h.
[0059] 3. CCK-8 treatment: At each time point, 10 μL of CCK-8 solution was added to each well, and the incubation was continued at 37°C, 5% CO2 for 2 hours.
[0060] 4. Absorbance measurement: The absorbance (OD value) of each well was measured at 450 nm wavelength using a microplate reader to assess cell proliferation.
[0061] As shown in Figure 13 , compared with the Vector control group, the OD values of the OE group at each time point were significantly increased, indicating that the overexpression of P4HA2 significantly promoted cell proliferation. On the contrary, the OD values of the Si-NC and Si-P4HA2 groups were significantly reduced in the Si-2 and Si-3 subgroups, indicating that the knockdown of P4HA2 inhibited cell proliferation. The CCK-8 experiment results confirmed the important role of P4HA2 in thyroid cancer cell proliferation, as its overexpression promoted cell proliferation, while its knockdown inhibited cell proliferation.
[0062] Example 6: Based on the foregoing examples, a colony formation experiment was performed.
[0063] In this study, we evaluated the effect of the P4HA2 gene on the proliferation capacity of thyroid cancer cells through a colony formation experiment. The experimental groups included Vector (empty vector control group), OE (P4HA2 overexpression group), and Si-NC (non-specific siRNA control group), Si-P4HA2 (P4HA2 specific siRNA knockdown group). The experimental results showed that in the OE group, the overexpression of the P4HA2 gene significantly promoted the formation of cell colonies, manifested as an increase in the number of colonies, indicating that the overexpression of the P4HA2 gene enhanced the colony formation ability of cells. On the contrary, in the Si-P4HA2 group, the knockdown of the P4HA2 gene led to a significant decrease in the number of colonies, reflecting that the knockdown of the P4HA2 gene inhibited the proliferation and colony formation ability of cells.
[0064] Colony formation experiment is an in vitro cell survival assay method to evaluate the ability of single cells to survive and reproduce to form colonies in treatment. The colony formation graph is shown in Figure 14 , which shows that in this experiment, the number of colonies in the overexpression group increased, while the number of colonies in the knockdown group decreased, directly reflecting the effect of the P4HA2 gene on the colony formation ability of thyroid cancer cells. The colony formation rate, i.e., the survival rate of inoculated cells, represents the number of adherent cells that survive and form colonies after inoculation of cells, which can reflect two important traits, cell population dependence and proliferation capacity.
[0065] In summary, the results of the colony formation experiment further confirm the important role of P4HA2 gene in thyroid cancer, as its overexpression promotes cell proliferation, while its knockdown inhibits cell proliferation.
[0066] Example 7: On the basis of the foregoing examples, a cell scratch experiment was performed.
[0067] The cell scratch experiment (Wound Healing Assay) is an in vitro experimental method that simulates the process of cell migration in the body, used to evaluate changes in cell migration ability and explore the molecular mechanisms related to cell migration. This experiment creates a "scratch" or "wound" on a cell monolayer, observes and records the process of cells migrating to fill the wound, and quantitatively analyzes the speed and efficiency of cell migration. The experimental groups include Vector (empty vector control group), OE (P4HA2 overexpression group) and Si-NC (non-specific siRNA control group), Si-P4HA2 (P4HA2 specific siRNA knockdown group). The cell scratch healing situation is shown in Figure 15 As shown in the figure, the experimental results show that at 24 hours of observation, the cells in the OE group healed faster than the Vector control group, indicating that the overexpression of P4HA2 significantly enhances the migration ability of cells. On the contrary, the healing rate of cells in the Si-P4HA2 group is slower than that in the Si-NC control group, indicating that knocking down the expression of P4HA2 gene inhibits the migration ability of cells. The results of the cell scratch experiment further confirm the key role of P4HA2 in thyroid cancer cell migration, as its overexpression promotes cell migration, while its knockdown inhibits cell migration.
[0068] Example 8: On the basis of the foregoing examples, a Transwell migration experiment was performed.
[0069] This study evaluated the effect of P4HA2 gene on the migration ability of thyroid cancer cells through the Transwell migration experiment. The experimental groups include Vector (empty vector control group), OE (P4HA2 overexpression group) and Si-NC (non-specific siRNA control group), Si-P4HA2 (P4HA2 specific siRNA knockdown group). The cell migration ability is shown in Figure 16 As shown in the figure, the experimental results show that in the OE group, the overexpression of P4HA2 gene significantly enhances the migration ability of cells, as the number of cells that have migrated through the polycarbonate membrane and into the lower chamber is greater than that of the control group. This result suggests that P4HA2 may play an important role in promoting the migration of thyroid cancer cells.
[0070] On the contrary, in the Si-P4HA2 group, the knockdown of P4HA2 gene significantly inhibited the migration ability of cells, which was manifested as the number of cells crossing the membrane and migrating to the lower chamber was less than that of the control group. This indicates that the expression level of P4HA2 is closely related to the migration ability of thyroid cancer cells, and the knockdown of P4HA2 can reduce the migration of cancer cells, which may have a potential therapeutic effect on inhibiting tumor metastasis. In summary, the results of the Transwell migration experiment further confirm that P4HA2 plays a key role in the migration of thyroid cancer, and its overexpression promotes the migration of cells, while its knockdown inhibits the migration of cells.
[0071] Example 9: A computer readable storage medium is also provided, and the computer readable storage medium stores a computer program which can be executed by a processor. The computer program is executed by the processor to perform at least one step of the aforementioned biomarker screening method for predicting papillary thyroid carcinoma, and achieve the same technical effects. To avoid repetition, this embodiment will not be described again.
[0072] Example 10: A computer device includes a memory, a processor, a communication interface, and a communication bus. The memory, the processor, and the communication interface communicate with each other through the communication bus. The memory is used to store a computer program. The processor is used to execute the computer program stored in the memory. The processor executes the computer program to perform at least one step of the aforementioned biomarker screening method for predicting papillary thyroid carcinoma, and achieve the same technical effects. To avoid repetition, this embodiment will not be described again.
[0073] Computer readable media includes permanent and non-permanent, removable and non-removable media, and can be implemented by any method or technology to store information. The information can be computer readable instructions, data structures, program modules or other data. Examples of computer storage media include, but are not limited to, phase change memory (PRAM), static random access memory (SRAM), dynamic random access memory (DRAM), other types of random access memory (RAM), read-only memory (ROM), electrically erasable programmable read-only memory (EEPROM), flash memory or other memory technologies, compact disc read-only memory (CD-ROM), digital versatile disc (DVD) or other optical storage, magnetic cassette, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other non-transmission medium that can be used to store information accessible by a computing device. According to the definition herein, computer readable media does not include transitory media such as modulated data signals and carriers.
[0074] The conventional techniques in the above-described embodiments are prior art known to those skilled in the art, and thus are not described in detail herein.
[0075] The specific embodiments described herein are merely illustrative of the principles of this application. Numerous modifications or adaptations will be readily apparent to those skilled in the art of this application, without departing from the spirit or scope of the application as defined by the following claims.
[0076] While the application has been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as illustrative and not restrictive in character, since various changes and / or modifications compatible with the scope and spirit of the application can be made by those skilled in the art to which the application pertains.
[0077] While the forgoing specification has shown and described certain specific embodiments of the application, it is to be understood that various omissions and substitutions and changes of the form and details of the devices or methodologies illustrated can be made by one skilled in the art without departing from the spirit of the present disclosure. Further, the specification is to be taken as an exemplification of the general inventive concepts disclosed herein. Additionally, various features and methods of the above-described embodiments can be used independently of one another or in various combinations. All possible combinations and subcombinations are intended to fall within the scope of the disclosure. Many of the embodiments described herein include similar components, and thus, these similar components can be interchanged between different embodiments. Although the application has been disclosed in the context of certain embodiments and examples, it will be understood that the application extends beyond the specifically disclosed embodiments to other alternative embodiments and / or uses and obvious modifications and equivalents thereof. Accordingly, it is not intended that the application be limited by the specific disclosures of preferred embodiments herein.
[0078] The details of this application are subject to known art.
Claims
1. A method for preparing a thyroid cancer activity inhibitor using siRNA that knocks down P4HA2, characterized in that: The molecular sequence of the siRNA is selected from at least one of the following sequences: SEQ IN NO1: GAAGGTGACTACCGAACAA, SEQ IN NO2: GCCGAATTCTTCACCTCTA, SEQ IN NO3: GCTGCAATTTGGCCTAAGA, wherein at least one of SEQ IN NO1 and SEQ IN NO2 is selected.
2. The use according to claim 1, wherein the thyroid cancer is papillary thyroid cancer.
3. A method for screening biomarkers for predicting papillary thyroid cancer, characterized in that include: 1) Based on weighted gene co-expression network analysis, calculate the Pearson correlation coefficient between genes, determine gene modules, construct co-expression networks, identify the association between modules and features, and screen potential hub genes; 2) A screening model was constructed based on support vector machine recursive feature elimination, LASSO regression, and random forest methods to obtain the intersection of the screening results, which was then deintersected with the potential hub genes to obtain an intersection list containing six candidate genes, including P4HA2, TBC1D4, PLSCR4, PRKCQ, AIF1L, and ANGPTL1; 3) Overexpression validation showed that P4HA2 promoted cancer cell proliferation, and knockdown validation showed that P4HA2 inhibited cancer cell proliferation. P4HA2 was screened and used as a biomarker for predicting papillary thyroid cancer or predicting early papillary thyroid cancer.
4. The method according to claim 3, wherein: In the step 1), the Pearson correlation coefficient between genes is calculated, the gene modules are determined, the co-expression network is constructed, the association between the modules and the features is identified, and the potential hub genes are screened out, specifically including: calculating the Pearson correlation coefficient between genes and selecting an appropriate soft threshold so that the network conforms to the scale-free network distribution; according to the soft threshold, the correlation matrix is converted into an adjacency matrix, and then a topological overlap matrix is generated; based on the topological overlap matrix, the genes are hierarchically clustered to construct a hierarchical clustering tree, in which different branches represent different modules; each module contains at least 30 genes, and then similar modules are merged according to a height threshold of 0.25; after the core genes of the core module are intersected with the DEGs, the potential hub genes are finally screened out.
5. The method according to claim 3, wherein: In the step 3), siRNA is used for knockdown verification, and the molecular sequence of the siRNA is selected from at least one of the following sequences: SEQ IN NO1: GAAGGTGACTACCGAACAA, SEQ IN NO2: GCCGAATTCTTCACCTCTA, SEQ IN NO3: GCTGCAATTTGGCCTAAGA, wherein at least one of SEQ IN NO1 and SEQ IN NO2 is selected.
6. The method according to claim 3, wherein: The support vector machine recursive feature elimination method recursively eliminates the least important features and combines the powerful classification ability of the support vector machine to identify key genes, specifically including: (1) Obtaining feature sample data , divide it into K subsets: So that: K samples are randomly selected from n sample data as the initial cluster centers, and the remaining sample data are respectively classified into the category of the cluster center closest to it, and the total distance within the category is minimized. The objective function is: ,in, Representing a collection The cluster center point is updated for the t+1th time using the following formula: , the new cluster center repeats the above steps for iteration until all data converge to the corresponding cluster set, and the sum of the squares of the distances from each data point to the cluster center in each cluster set is minimized or reaches a predetermined value or iterates to the upper limit. The set of all cluster centers is recorded as ; (2) Use the SVM-RFE algorithm to sort each subset of the completed clustering in step (1) and select Key features, all key features form a new feature set ; (3) Use SVM-RFE algorithm again Sort the new feature set composed, get the final importance analysis result, and obtain the key feature set , the number of features is recorded as ,and .
7. A computer device comprising a memory, a processor, a communication interface, and a communication bus; wherein: The memory, processor, and communication interface communicate with each other through the communication bus; the memory is used to store computer programs; the processor is used to execute the computer programs stored in the memory, and is characterized in that: when the processor executes the computer program, it implements at least one step of the method for screening biomarkers for predicting papillary thyroid cancer according to any one of claims 3-6.
8. A computer-readable storage medium having a computer program stored thereon, characterized in that: When the computer program is executed by a processor, at least one step of the method for screening biomarkers for predicting papillary thyroid cancer according to any one of claims 3 to 6 is implemented.
Citation Information
Cited By
Screening method of biomarker for auxiliary diagnosis of small cell lung cancer
CN121528316A
A screening method for biomarkers for aiding in the diagnosis of small cell lung cancer
CN121528316B
